CAS 151581-24-7
:Acido 4H-1-benzopirano-2-carbossilico, 7-[[(1S,2E,4Z)-9-(4-acetil-3-idrossi-2-propilfenossi)-1-[(R)-idrossi[3-(trifluorometil)fenil]metil]-2,4-nonadien-1-il]tio]-4-osso-
- 4H-1-Benzopyran-2-carboxylicacid,7-[[(1S,2E,4Z)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-[(R)-hydroxy[3-(trifluoromethyl)phenyl]methyl]-2,4-nonadienyl]thio]-4-oxo-(9CI)
- 4H-1-Benzopyran-2-carboxylic acid, 7-[[9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-[hydroxy[3-(trifluoromethyl)phenyl]methyl]-2,4-nonadienyl]thio]-4-oxo-,[S-[R*,S*-(E,Z)]]-
- Iralukast
Iralukast (CGP 45715A)
CAS:Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1.Formula:C38H37F3O8SColore e forma:SolidPeso molecolare:710.76Iralukast
CAS:Iralukast is a leukotriene receptor antagonist that blocks the bronchoconstrictor response. It is used in the treatment of bronchial asthma, chronic obstructive pulmonary disease, and bowel diseases such as ulcerative colitis. Iralukast is not absorbed into the bloodstream and therefore does not inhibit the production of the inflammatory mediators that are responsible for these diseases. Iralukast binds to receptors on cells lining the airways, preventing activation of cells by leukotrienes, which are released by mast cells in response to an allergen or irritant. This binding prevents the release of inflammatory mediators from mast cells and reduces bronchial reactivity. Iralukast also has been shown to inhibit the enzyme activity of phospholipase A2 (PLA2), which has been implicated in inflammatory bowel disease.
Formula:C38H37F3O8SPurezza:Min. 95%Peso molecolare:710.21612

